What Would Slower New Drug Sales Do To Vertex Stock

For questions about this article or underlying research, email [email protected].

Vertex Pharmaceuticals (VRTX) stock trades at 30.0 times earnings, against 22.6 for the S&P 500. Part of that premium may be a bet on its drugs beyond cystic fibrosis. On its August 3, 2026 call, management kept its sales outlook for those drugs, but said it has more work to do on access for JOURNAVX, its acute pain drug. So are Vertex's new drugs actually losing pace?

Vertex's New Drug Sales Are Still Climbing

The new drugs did not lose pace through the second quarter of 2026. CASGEVY brought in $76 million that quarter, against $30 million a year earlier, while JOURNAVX generated $50 million, against $12 million.

Part of the JOURNAVX rise appears to have run ahead of demand. Its revenue grew about 70% from the first quarter, while prescriptions grew about 45%. Management also said JOURNAVX's second-quarter revenue was helped by inventory building in the sales channel after a first-quarter drawdown.

JOURNAVX does lag on access and price. Prescriptions are growing faster than unrestricted payer access, management said, and as a result it now expects the gap between the drug's list price and what Vertex collects to settle in line with other branded oral medicines only in the first half of 2027.

How Much Of Vertex's Sales Would A Slowdown Touch?

Based on management's own outlook, a slowdown would touch about 4% of Vertex's 2026 sales. Management expects at least $500 million from its drugs outside cystic fibrosis, against total revenue guided at $13.1 billion to $13.2 billion.

That small share does not show what a holder pays for. Vertex's biggest drug, TRIKAFTA/KAFTRIO, brought in $10.3 billion of the company's $12.0 billion revenue in fiscal 2025. Its revenue grew less than 1% that year, after 14.5% in fiscal 2024. Cystic fibrosis sales as a whole still grew 11% in the second quarter of 2026, led in the U.S. by ALYFTREK.

Management expects both CASGEVY and JOURNAVX to become multibillion-dollar assets. If those drugs slowed, a holder would still be paying 30.0 times earnings, against 22.6 for the S&P 500, for a company whose sales come mostly from cystic fibrosis.

Can Vertex Afford A Slower Launch?

Yes, on the cash it generates. Vertex produced $3.8 billion in free cash flow over the twelve months to June 30, 2026, so the company could absorb slower new drug sales without straining its finances.

At that date, Vertex held $7.85 billion in cash and short-term investments, against $1.98 billion of debt. That was before its deal to buy Crinetics for about $8.8 billion, net of cash acquired, which Vertex completed on September 1, 2026. Vertex planned to fund it with cash on hand and a $4.5 billion term loan, so the June figures above do not show the deal. Vertex planned to fund it with cash on hand and a $4.5 billion term loan, so after the deal it would hold less cash and more debt than in June.

What Would Show Vertex's New Drugs Slowing?

Vertex reports quarterly revenue for CASGEVY and JOURNAVX, and a slowdown would appear there first, though management expects quarter-to-quarter swings in JOURNAVX inventory and CASGEVY revenue. Because CASGEVY revenue tracks the timing of patient infusions, the number of patients starting treatment is worth watching beside it. Management said the second quarter of 2026 was the third in a row with more than 100 patients starting CASGEVY treatment. For the pain drug, the matching measure is JOURNAVX prescriptions, about 535,000 in that quarter.

Vertex's new drugs are still growing quickly in sales and still make up a small part of what the company sells. The first read on that pace is CASGEVY and JOURNAVX revenue in Vertex's third-quarter report, expected in November 2026.

Does This Mean You Should Act On VRTX?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.